Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.